11/20
04:00 pm
iva
Combined General Meeting of December 11, 2024 - Availability of the preparatory documents
Medium
Report
Combined General Meeting of December 11, 2024 - Availability of the preparatory documents
11/15
04:00 pm
iva
Inventiva will present data from the final analysis of the Phase 2 study evaluating the combination of lanifibranor with empagliflozin in patients with MASH and T2D at the AASLD The Liver Meeting® late-breaker session
Low
Report
Inventiva will present data from the final analysis of the Phase 2 study evaluating the combination of lanifibranor with empagliflozin in patients with MASH and T2D at the AASLD The Liver Meeting® late-breaker session
11/12
08:19 am
iva
Inventiva S.A. (NASDAQ: IVA) is now covered by analysts at UBS Group AG. They set a "neutral" rating and a $3.00 price target on the stock.
Low
Report
Inventiva S.A. (NASDAQ: IVA) is now covered by analysts at UBS Group AG. They set a "neutral" rating and a $3.00 price target on the stock.
10/30
04:00 pm
iva
Inventiva announces the positive recommendation of the fifth DMC of the NATiV3 Phase 3 clinical trial with lanifibranor in patients with MASH
Medium
Report
Inventiva announces the positive recommendation of the fifth DMC of the NATiV3 Phase 3 clinical trial with lanifibranor in patients with MASH
10/21
08:30 am
iva
Inventiva announces a late breaker abstract from LEGEND, Phase 2 trial, evaluating lanifibranor in combination with empagliflozin in MASH at the AASLD The Liver Meeting® 2024
Low
Report
Inventiva announces a late breaker abstract from LEGEND, Phase 2 trial, evaluating lanifibranor in combination with empagliflozin in MASH at the AASLD The Liver Meeting® 2024
10/15
01:32 pm
iva
Inventiva S.A. (NASDAQ: IVA) had its price target lowered by analysts at HC Wainwright from $14.00 to $13.00. They now have a "buy" rating on the stock.
Medium
Report
Inventiva S.A. (NASDAQ: IVA) had its price target lowered by analysts at HC Wainwright from $14.00 to $13.00. They now have a "buy" rating on the stock.
10/14
01:45 pm
iva
Inventiva announces the availability of a prospectus in connection with its financing through the issuance of ordinary shares and pre-funded warrants
Medium
Report
Inventiva announces the availability of a prospectus in connection with its financing through the issuance of ordinary shares and pre-funded warrants
10/14
02:35 am
iva
Inventiva announces Filing of 2024 Half-Year Report – Conditions for Accessing or Consulting the Report
High
Report
Inventiva announces Filing of 2024 Half-Year Report – Conditions for Accessing or Consulting the Report
10/14
02:30 am
iva
Inventiva announces financing of up to €348 million to advance the NATiV3 Phase 3 MASH study
High
Report
Inventiva announces financing of up to €348 million to advance the NATiV3 Phase 3 MASH study
9/26
02:11 pm
iva
Inventiva S.A. (NASDAQ: IVA) had its price target lowered by analysts at HC Wainwright from $22.00 to $14.00. They now have a "buy" rating on the stock.
Low
Report
Inventiva S.A. (NASDAQ: IVA) had its price target lowered by analysts at HC Wainwright from $22.00 to $14.00. They now have a "buy" rating on the stock.
9/26
12:16 pm
iva
Inventiva S.A. (NASDAQ: IVA) had its price target lowered by analysts at Stifel Nicolaus from $25.00 to $20.00. They now have a "buy" rating on the stock.
Low
Report
Inventiva S.A. (NASDAQ: IVA) had its price target lowered by analysts at Stifel Nicolaus from $25.00 to $20.00. They now have a "buy" rating on the stock.
9/25
04:00 pm
iva
Inventiva provides a corporate update and reports its unaudited 2024 first-half financial results
High
Report
Inventiva provides a corporate update and reports its unaudited 2024 first-half financial results